Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$142.00
0.400.28%
Pre-Market: 7:36 PM EDT
Comments
Loading...
Biogen Analyst Ratings and Price Targets | NASDAQ:BIIB | Benzinga
Biogen Inc has a consensus price target of $224.58 based on the ratings of 29 analysts. The high is $342 issued by HSBC on May 3, 2024. The low is $135 issued by Piper Sandler on February 18, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, Scotiabank, and BMO Capital on February 18, 2025, February 13, 2025, and February 13, 2025, respectively. With an average price target of $166 between Piper Sandler, Scotiabank, and BMO Capital, there's an implied 16.90% upside for Biogen Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Scotiabank
BMO Capital
Morgan Stanley
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Biogen
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/18/2025 | Buy Now | -4.93% | Piper Sandler | Christopher Raymond57% | $138 → $135 | Reiterates | Neutral → Neutral | Get Alert |
| 02/13/2025 | Buy Now | 57.75% | Scotiabank | George Farmer48% | $244 → $224 | Maintains | Sector Outperform | Get Alert |
| 02/13/2025 | Buy Now | -2.11% | BMO Capital | Evan Seigerman64% | $156 → $139 | Maintains | Market Perform | Get Alert |
| 02/13/2025 | Buy Now | 10.56% | Morgan Stanley | Matthew Harrison60% | $192 → $157 | Maintains | Equal-Weight | Get Alert |
| 02/13/2025 | Buy Now | 72.54% | Goldman Sachs | Salveen Richter52% | $281 → $245 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 58.45% | RBC Capital | Brian Abrahams52% | $231 → $225 | Maintains | Outperform | Get Alert |
| 02/13/2025 | Buy Now | 2.11% | Citigroup | Geoff Meacham63% | $160 → $145 | Maintains | Neutral | Get Alert |
| 02/13/2025 | Buy Now | -1.41% | Wells Fargo | Mohit Bansal73% | $165 → $140 | Maintains | Equal-Weight | Get Alert |
| 02/13/2025 | Buy Now | 69.72% | HC Wainwright & Co. | Andrew Fein57% | $300 → $241 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 47.89% | Truist Securities | Srikripa Devarakonda47% | $220 → $210 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 86.62% | Canaccord Genuity | Sumant Kulkarni43% | $298 → $265 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | — | Needham | Ami Fadia62% | — | Reiterates | Hold → Hold | Get Alert |
| 01/28/2025 | Buy Now | 12.68% | Citigroup | Geoff Meacham63% | $190 → $160 | Maintains | Neutral | Get Alert |
| 01/10/2025 | Buy Now | 16.2% | Wells Fargo | Mohit Bansal73% | $190 → $165 | Maintains | Equal-Weight | Get Alert |
| 01/08/2025 | Buy Now | 54.93% | Truist Securities | Srikripa Devarakonda47% | $302 → $220 | Maintains | Buy | Get Alert |
| 01/02/2025 | Buy Now | -2.82% | Piper Sandler | Christopher Raymond57% | $315 → $138 | Downgrade | Overweight → Neutral | Get Alert |
| 12/20/2024 | Buy Now | 15.49% | BMO Capital | Evan Seigerman64% | $230 → $164 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/10/2024 | Buy Now | 25.35% | B of A Securities | Tim Anderson53% | → $178 | Reinstates | → Neutral | Get Alert |
| 12/09/2024 | Buy Now | 26.76% | Jefferies | Michael Yee56% | $250 → $180 | Downgrade | Buy → Hold | Get Alert |
| 11/21/2024 | Buy Now | 45.77% | Mizuho | Salim Syed44% | $251 → $207 | Maintains | Outperform | Get Alert |
| 11/18/2024 | Buy Now | 90.14% | Needham | Ami Fadia62% | $270 → $270 | Downgrade | Buy → Hold | Get Alert |
| 11/15/2024 | Buy Now | 111.27% | Baird | Brian Skorney58% | $294 → $300 | Maintains | Outperform | Get Alert |
| 11/15/2024 | Buy Now | — | Wolfe Research | Alexandria Hammond43% | — | Initiates | → Peer Perform | Get Alert |
| 11/14/2024 | Buy Now | 33.8% | Citigroup | Geoff Meacham63% | → $190 | Initiates | → Neutral | Get Alert |
| 11/04/2024 | Buy Now | 47.89% | JP Morgan | Chris Schott61% | $220 → $210 | Maintains | Neutral | Get Alert |
| 10/31/2024 | Buy Now | 79.58% | Oppenheimer | Jay Olson62% | $270 → $255 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 26.76% | Barclays | Carter Gould58% | $190 → $180 | Maintains | Equal-Weight | Get Alert |
| 10/31/2024 | Buy Now | 93.66% | TD Cowen | Phil Nadeau66% | $300 → $275 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 111.27% | HC Wainwright & Co. | Andrew Fein57% | $300 → $300 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 90.14% | Needham | Ami Fadia62% | $270 → $270 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 43.66% | Morgan Stanley | Matthew Harrison60% | $285 → $204 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 10/30/2024 | Buy Now | 90.14% | Needham | Ami Fadia62% | $270 → $270 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2024 | Buy Now | 61.97% | BMO Capital | Evan Seigerman64% | $260 → $230 | Maintains | Outperform | Get Alert |
| 10/10/2024 | Buy Now | — | Raymond James | Danielle Brill43% | — | Reinstates | → Market Perform | Get Alert |
| 10/04/2024 | Buy Now | 89.44% | RBC Capital | Brian Abrahams52% | $292 → $269 | Maintains | Outperform | Get Alert |
| 10/03/2024 | Buy Now | 42.25% | UBS | Colin Bristow41% | $234 → $202 | Maintains | Neutral | Get Alert |
| 09/24/2024 | Buy Now | 100.7% | Needham | Ami Fadia62% | $285 → $285 | Reiterates | Buy → Buy | Get Alert |
| 09/23/2024 | Buy Now | 44.37% | Wedbush | Laura Chico48% | $210 → $205 | Maintains | Neutral | Get Alert |
| 09/19/2024 | Buy Now | 105.63% | RBC Capital | Brian Abrahams52% | $292 → $292 | Reiterates | Outperform → Outperform | Get Alert |
| 09/09/2024 | Buy Now | 105.63% | Cantor Fitzgerald | Eric Schmidt31% | $292 → $292 | Reiterates | Overweight → Overweight | Get Alert |
| 09/04/2024 | Buy Now | 100.7% | Needham | Ami Fadia62% | $285 → $285 | Reiterates | Buy → Buy | Get Alert |
| 08/19/2024 | Buy Now | 100.7% | Needham | Ami Fadia62% | $285 → $285 | Reiterates | Buy → Buy | Get Alert |
| 08/06/2024 | Buy Now | 76.76% | Mizuho | Salim Syed44% | $277 → $251 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 112.68% | Truist Securities | Srikripa Devarakonda47% | $340 → $302 | Reiterates | Buy → Buy | Get Alert |
| 08/05/2024 | Buy Now | 100.7% | Needham | Ami Fadia62% | $288 → $285 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 105.63% | RBC Capital | Brian Abrahams52% | $282 → $292 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | 58.45% | Wells Fargo | Mohit Bansal73% | $240 → $225 | Maintains | Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | 71.83% | Scotiabank | George Farmer48% | $275 → $244 | Maintains | Sector Outperform | Get Alert |
| 08/02/2024 | Buy Now | 33.8% | Barclays | Carter Gould58% | $200 → $190 | Maintains | Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | 47.89% | Wedbush | Laura Chico48% | $215 → $210 | Maintains | Neutral | Get Alert |
| 08/01/2024 | Buy Now | 102.82% | Needham | Ami Fadia62% | $288 → $288 | Reiterates | Buy → Buy | Get Alert |
| 07/29/2024 | Buy Now | 107.04% | Baird | Brian Skorney58% | $316 → $294 | Maintains | Outperform | Get Alert |
| 07/26/2024 | Buy Now | 107.04% | Needham | Ami Fadia62% | $294 → $294 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2024 | Buy Now | 120.42% | Piper Sandler | Christopher Raymond57% | $335 → $313 | Maintains | Overweight | Get Alert |
| 06/28/2024 | Buy Now | 107.04% | Needham | Ami Fadia62% | $294 → $294 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2024 | Buy Now | 123.24% | RBC Capital | Brian Abrahams52% | $317 → $317 | Reiterates | Outperform → Outperform | Get Alert |
| 06/26/2024 | Buy Now | 123.24% | RBC Capital | Brian Abrahams52% | $317 → $317 | Reiterates | Outperform → Outperform | Get Alert |
| 06/05/2024 | Buy Now | 123.24% | RBC Capital | Brian Abrahams52% | $317 → $317 | Reiterates | Outperform → Outperform | Get Alert |
| 05/29/2024 | Buy Now | 123.24% | RBC Capital | Brian Abrahams52% | → $317 | Reiterates | Outperform → Outperform | Get Alert |
| 05/23/2024 | Buy Now | 111.27% | HC Wainwright & Co. | Andrew Fein57% | $300 → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2024 | Buy Now | 107.04% | Needham | Ami Fadia62% | $294 → $294 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 139.44% | Truist Securities | Robyn Karnauskas56% | $340 → $340 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | 140.85% | HSBC | Morten Herholdt40% | $339 → $342 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | 90.14% | Oppenheimer | Jay Olson62% | $270 → $270 | Maintains | Outperform | Get Alert |
| 04/25/2024 | Buy Now | 107.04% | Needham | Ami Fadia62% | $294 → $294 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | 40.85% | Barclays | Carter Gould58% | $215 → $200 | Maintains | Equal-Weight | Get Alert |
| 04/25/2024 | Buy Now | 51.41% | Wedbush | Laura Chico48% | $213 → $215 | Maintains | Neutral | Get Alert |
| 04/25/2024 | Buy Now | 111.27% | HC Wainwright & Co. | Andrew Fein57% | $325 → $300 | Maintains | Buy | Get Alert |
| 04/24/2024 | Buy Now | 107.04% | Needham | Ami Fadia62% | $294 → $294 | Reiterates | Buy → Buy | Get Alert |
| 04/19/2024 | Buy Now | 90.14% | Oppenheimer | Jay Olson62% | $290 → $270 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | 50.7% | UBS | Colin Bristow41% | $250 → $214 | Maintains | Neutral | Get Alert |
| 04/17/2024 | Buy Now | 50% | Wedbush | Laura Chico48% | $245 → $213 | Maintains | Neutral | Get Alert |
| 04/12/2024 | Buy Now | 83.1% | B of A Securities | Geoff Meacham63% | $280 → $260 | Maintains | Neutral | Get Alert |
| 04/11/2024 | Buy Now | 69.01% | JP Morgan | Chris Schott61% | $270 → $240 | Maintains | Neutral | Get Alert |
| 04/04/2024 | Buy Now | 51.41% | Barclays | Carter Gould58% | $230 → $215 | Maintains | Equal-Weight | Get Alert |
| 03/25/2024 | Buy Now | 139.44% | Truist Securities | Robyn Karnauskas56% | → $340 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 156.34% | RBC Capital | Brian Abrahams52% | $364 → $364 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | Buy Now | 95.07% | Mizuho | Salim Syed44% | $355 → $277 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 119.01% | Cantor Fitzgerald | Eric Schmidt31% | $311 → $311 | Reiterates | Overweight → Overweight | Get Alert |
| 02/20/2024 | Buy Now | 114.79% | Canaccord Genuity | Sumant Kulkarni43% | $310 → $305 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 76.06% | UBS | Colin Bristow41% | $276 → $250 | Maintains | Neutral | Get Alert |
| 02/14/2024 | Buy Now | 128.87% | HC Wainwright & Co. | Andrew Fein57% | $325 → $325 | Reiterates | Buy → Buy | Get Alert |
| 02/14/2024 | Buy Now | 122.54% | Baird | Brian Skorney58% | $333 → $316 | Maintains | Outperform | Get Alert |
| 02/14/2024 | Buy Now | 128.87% | Piper Sandler | Christopher Raymond57% | $350 → $325 | Maintains | Overweight | Get Alert |
| 02/14/2024 | Buy Now | 100.7% | BMO Capital | Evan Seigerman64% | $295 → $285 | Maintains | Outperform | Get Alert |
| 02/14/2024 | Buy Now | 104.23% | Oppenheimer | Jay Olson62% | $295 → $290 | Maintains | Outperform | Get Alert |
| 02/14/2024 | Buy Now | 156.34% | RBC Capital | Brian Abrahams52% | $379 → $364 | Maintains | Outperform | Get Alert |
| 02/14/2024 | Buy Now | 69.01% | Wells Fargo | Mohit Bansal73% | $315 → $240 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 02/14/2024 | Buy Now | 111.27% | Needham | Ami Fadia62% | $305 → $300 | Maintains | Buy | Get Alert |
| 02/13/2024 | Buy Now | 114.79% | Needham | Ami Fadia62% | $305 → $305 | Reiterates | Buy → Buy | Get Alert |
| 01/30/2024 | Buy Now | 107.75% | Oppenheimer | Jay Olson62% | → $295 | Reiterates | Outperform → Outperform | Get Alert |
| 01/25/2024 | Buy Now | 94.37% | UBS | Colin Bristow41% | $311 → $276 | Downgrade | Buy → Neutral | Get Alert |
| 01/24/2024 | Buy Now | 94.37% | UBS | Colin Bristow41% | → $276 | Downgrade | Buy → Neutral | Get Alert |
| 12/20/2023 | Buy Now | 119.01% | Cantor Fitzgerald | Eric Schmidt31% | $311 → $311 | Reiterates | Overweight → Overweight | Get Alert |
| 12/18/2023 | Buy Now | 107.75% | Oppenheimer | Jay Olson62% | $280 → $295 | Maintains | Outperform | Get Alert |
| 12/14/2023 | Buy Now | 102.11% | Stifel | Paul Matteis44% | $315 → $287 | Maintains | Buy | Get Alert |
| 12/07/2023 | Buy Now | 99.3% | Raymond James | Danielle Brill43% | → $283 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/10/2023 | Buy Now | 162.68% | Morgan Stanley | Matthew Harrison60% | $361 → $373 | Maintains | Overweight | Get Alert |
| 11/09/2023 | Buy Now | 107.75% | BMO Capital | Evan Seigerman64% | $314 → $295 | Maintains | Outperform | Get Alert |
| 11/09/2023 | Buy Now | 155.63% | RBC Capital | Brian Abrahams52% | $351 → $363 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Biogen (BIIB) stock?
The latest price target for Biogen (NASDAQ:BIIB) was reported by Piper Sandler on February 18, 2025. The analyst firm set a price target for $135.00 expecting BIIB to fall to within 12 months (a possible -4.93% downside). 75 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biogen (BIIB)?
The latest analyst rating for Biogen (NASDAQ:BIIB) was provided by Piper Sandler, and Biogen reiterated their neutral rating.
When was the last upgrade for Biogen (BIIB)?
The last upgrade for Biogen Inc happened on December 7, 2023 when Raymond James raised their price target to $283. Raymond James previously had a market perform for Biogen Inc.
When was the last downgrade for Biogen (BIIB)?
The last downgrade for Biogen Inc happened on January 2, 2025 when Piper Sandler changed their price target from $315 to $138 for Biogen Inc.
When is the next analyst rating going to be posted or updated for Biogen (BIIB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biogen was filed on February 18, 2025 so you should expect the next rating to be made available sometime around February 18, 2026.
Is the Analyst Rating Biogen (BIIB) correct?
While ratings are subjective and will change, the latest Biogen (BIIB) rating was a reiterated with a price target of $138.00 to $135.00. The current price Biogen (BIIB) is trading at is $142.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.